NCT04728321View on ClinicalTrials.gov

A Study of Anti-PD-1/CTLA-4 Bispecific AK104 Alone or in Combination With Lenvatinib in Advanced Hepatocellular Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

January 27, 2021

Primary Completion Date

August 2, 2022

Study Completion Date

August 2, 2023

Conditions
Hepatocellular Carcinoma
Interventions
BIOLOGICAL

AK104 lenvatinib

Subjects will receive AK104 and lenvatinib until disease progression or for a maximum of 24 months

BIOLOGICAL

AK104

Subjects will receive AK104 until disease progression or for a maximum of 24 months

Trial Locations (1)

310000

The first affilited hospital zhejiang university school of medcine, Hangzhou

Sponsors

Lead Sponsor

Akeso
All Listed Sponsors
collaborator

Akeso Pharmaceuticals, Inc.

OTHER

lead

Akeso

INDUSTRY